Drug intelligence / Profile preview

QP-6211

Development stage: Unknown
Lead developer: Nanjing Delova Biotech
Modality: Small Molecules
Administration: Injection

Overview

QP-6211 is an investigational analgesic drug developed by Nanjing Qingpu Biotechnology for the management of postoperative pain, particularly following hemorrhoidectomy. It is being evaluated for its efficacy, safety, and pharmacokinetic properties in clinical trials. The drug is administered via injection and has reached Phase 2/3 clinical development for postoperative pain indications. While the precise mechanism of action has not been publicly disclosed, it is classified as a small molecule analgesic intended to provide effective pain relief after surgical procedures[1][3][4].

Beyond the preview

Go deeper on QP-6211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QP-6211.

Explore the full profile